BioLine Rx Analyst Ratings
BioLine Rx Analyst Ratings
While ratings are subjective and will change, the latest BioLine Rx (BLRX) rating was a reiterated with a price target of $0.00 to $21.00. The current price BioLine Rx (BLRX) is trading at is $1.61, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 1204.35% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 09/15/2023 | 1204.35% | HC Wainwright & Co. | $19 → $21 | Maintains | Buy |
| 08/31/2023 | 1080.12% | HC Wainwright & Co. | → $19 | Reiterates | Buy → Buy |
| 05/25/2023 | 148.45% | Oppenheimer | → $4 | Reiterates | → Outperform |
| 02/23/2021 | 1080.12% | HC Wainwright & Co. | $22 → $19 | Maintains | Buy |
| 12/16/2020 | 1266.46% | HC Wainwright & Co. | $18 → $22 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/20/2023 | 1204.35% | HC Wainwright & Co. | → 21 美元 | 重申 | 購買 → 購買 |
| 09/15/2023 | 1204.35% | HC Wainwright & Co. | 19 美元 → 21 美元 | 維護 | 買 |
| 08/31/2023 | 1080.12% | HC Wainwright & Co. | → 19 美元 | 重申 | 購買 → 購買 |
| 05/25/2023 | 148.45% | 奧本海默 | → 4 美元 | 重申 | → 跑贏大盤 |
| 2021 年 2 月 23 日 | 1080.12% | HC Wainwright & Co. | 22 美元 → 19 美元 | 維護 | 買 |
| 2020 年 12 月 16 日 | 1266.46% | HC Wainwright & Co. | 18 美元 → 22 美元 | 維護 | 買 |
What is the target price for BioLine Rx (BLRX)?
BioLine Rx (BLRX) 的目標價格是多少？
The latest price target for BioLine Rx (NASDAQ: BLRX) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $21.00 expecting BLRX to rise to within 12 months (a possible 1204.35% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月20日公佈了BioLine Rx（納斯達克股票代碼：BLRX）的最新目標股價。該分析公司將目標股價定爲21.00美元，預計BLRX將在12個月內升至12個月內（可能上漲1204.35％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for BioLine Rx (BLRX)?
BioLine Rx（BLRX）的最新分析師評級是多少？
The latest analyst rating for BioLine Rx (NASDAQ: BLRX) was provided by HC Wainwright & Co., and BioLine Rx reiterated their buy rating.
BioLine Rx（納斯達克股票代碼：BLRX）的最新分析師評級由HC Wainwright & Co. 提供，BioLine Rx重申了買入評級。
When is the next analyst rating going to be posted or updated for BioLine Rx (BLRX)?
BioLine Rx（BLRX）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLine Rx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLine Rx was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與BioLine Rx的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。BioLine Rx的最新評級是在2023年11月20日公佈的，因此您應該預計下一個評級將在2024年11月20日左右公佈。
Is the Analyst Rating BioLine Rx (BLRX) correct?
分析師評級 BioLine Rx (BLRX) 正確嗎？
While ratings are subjective and will change, the latest BioLine Rx (BLRX) rating was a reiterated with a price target of $0.00 to $21.00. The current price BioLine Rx (BLRX) is trading at is $1.61, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的BioLine Rx（BLRX）評級得到了重申，目標股價爲0.00美元至21.00美元。BioLine Rx（BLRX）的當前交易價格爲1.61美元，在分析師的預測區間內。
